Physician profile

John H Lohrey

Hematology & Oncology · Dallas, TX

NPI 1780631911

$318.66

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

See the full distribution for Hematology & Oncology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Education$17.02

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Lilly USA, LLC $111.87 2021-2022
Foundation Medicine, INC. $71.07 2019-2022
Daiichi Sankyo INC. $26.66 2022
Genzyme Corporation $22.68 2019
Janssen Biotech, INC. $19.16 2019
Regeneron Healthcare Solutions, INC. $17.02 2024 Libtayo
Genentech USA, INC. $15.43 2019
Gilead Sciences, INC. $11.92 2021
Astrazeneca Pharmaceuticals LP $11.82 2019
Taiho Oncology, INC. $11.03 2019

1 company reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John H Lohrey

$318.66

in general payments reported 2019-2025

Years
2019-2024
Top company
Lilly USA, LLC

https://glasscript.com/doctor/216974/john-h-lohrey

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.